Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut J Ehrlich

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Journal of Clinical Immunology|May 18, 2006
Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiencyJoseph A Church, Heinz Leibl, Mark R Stein, et al.
Clinical and Vaccine Immunology : CVI|April 18, 2014
Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patientsMaikel V W van der Velden, Alexander Geisberger, Thomas Dvorak, et al.
Plos One|December 5, 2012
Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptideAlfred T Welzel, Angela D Williams, Helen P McWilliams-Koeppen, et al.
Vaccine|October 18, 2011
Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trialGerald Aichinger, Hartmut J Ehrlich, John G Aaskov, et al.
The New England Journal of Medicine|June 14, 2008
A clinical trial of a whole-virus H5N1 vaccine derived from cell cultureHartmut J Ehrlich, Markus Müller, Helen M L Oh, et al.
Vaccine|November 15, 2011
Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccinePaul A Tambyah, Annelies Wilder-Smith, Borislava G Pavlova, et al.
The Journal of Infectious Diseases|September 18, 2013
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric populationMaikel V W van der Velden, Richard Fritz, Eva Maria Pöllabauer, et al.
The Journal of Infectious Diseases|August 29, 2009
A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responsesHartmut J Ehrlich, Markus Müller, Sandor Fritsch, et al.
Plos One|February 27, 2010
A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse modelsOtfried Kistner, Brian A Crowe, Walter Wodal, et al.
The Lancet. Infectious Diseases|May 14, 2013
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trialNina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of Clinical Immunology|May 18, 2006
Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiencyJoseph A Church, Heinz Leibl, Mark R Stein, et al.
Clinical and Vaccine Immunology : CVI|April 18, 2014
Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patientsMaikel V W van der Velden, Alexander Geisberger, Thomas Dvorak, et al.
Plos One|December 5, 2012
Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptideAlfred T Welzel, Angela D Williams, Helen P McWilliams-Koeppen, et al.
Vaccine|October 18, 2011
Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trialGerald Aichinger, Hartmut J Ehrlich, John G Aaskov, et al.
The New England Journal of Medicine|June 14, 2008
A clinical trial of a whole-virus H5N1 vaccine derived from cell cultureHartmut J Ehrlich, Markus Müller, Helen M L Oh, et al.
Vaccine|November 15, 2011
Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccinePaul A Tambyah, Annelies Wilder-Smith, Borislava G Pavlova, et al.
The Journal of Infectious Diseases|September 18, 2013
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric populationMaikel V W van der Velden, Richard Fritz, Eva Maria Pöllabauer, et al.
The Journal of Infectious Diseases|August 29, 2009
A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responsesHartmut J Ehrlich, Markus Müller, Sandor Fritsch, et al.
Plos One|February 27, 2010
A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse modelsOtfried Kistner, Brian A Crowe, Walter Wodal, et al.
The Lancet. Infectious Diseases|May 14, 2013
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trialNina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger, et al.
Pageof 5